Breakthrough in Lung Cancer Vaccine: 100% Prevention of Brain Metastasis
- Targeting Sugar Molecules in Sugar-Immune Therapy
- Monkeypox Initial Infection Provides Protection Against Secondary Infection
- What is Genetic Toxicity of Base Editing and Prime Editing?
- What is the Scientific Foundation of mRNA Technology?
- This amino acid can significantly alleviate post-COVID-19 sequelae!
- What are Challenges in CAR-T Cell Therapy for Cancer treatment?
Breakthrough in Lung Cancer Vaccine: 100% Prevention of Brain Metastasis and Increased Cure Rate
- Cardiovascular Diseases Linked to COVID-19 Infections
- FDA’s First Potential TIL Therapy Review Delayed: How to Understand FDA’s “Resource Constraints”?
- A Chinese Doctor Accused of Accepting Bribes Totaling US$166 Million
- Nuclear contaminated water: Japanese government paid bribes and corrected the IAEA report
- Top 20 Companies of Instruments and Medical Equipment In The World
- The first DMD gene therapy SRP-9001 may cost 4 million US dollars
- How long can the patient live after heart stent surgery?
Breakthrough in Lung Cancer Vaccine: 100% Prevention of Brain Metastasis and Increased Cure Rate.
Smallpox claimed the lives of 300 million people in the 20th century, and it took humanity nearly 200 years to completely eradicate it. In 1980, the World Health Organization officially declared the eradication of smallpox, with the smallpox vaccine playing a pivotal role.
So, could there be a “lung cancer vaccine” to eradicate lung cancer?
Understanding Cancer Vaccines
Before answering this question, let’s first understand what cancer vaccines are. Cancer vaccines primarily use tumor-associated antigens to stimulate the body’s immune system against cancer. Currently, these vaccines can be broadly categorized as preventive or therapeutic.
Preventive vaccines work by preventing or eradicating viruses to prevent cancer, with the HPV vaccine being a common example. Therapeutic vaccines, on the other hand, activate the body’s immune functions to control and eliminate cancer cells.
The principle behind therapeutic vaccines is to stimulate dendritic cells in the immune system using the vaccine.
When these cells present tumor antigens on their surface, they induce cytotoxic T lymphocytes to target and eliminate specific cancer cells.
They also stimulate and assist T cells in secreting cytokines, indirectly enhancing the attack on cancer cells.
Currently, most cancer vaccines are in experimental or early clinical trial stages, with very few vaccines available on the market.
Two notable cancer vaccines are Provenge for treating prostate cancer and the Cuban Cimavax vaccine for non-small cell lung cancer.
Novel Vaccine for ALK-Positive Lung Cancer
Recent research published in Nature Cancer confirms the effectiveness of a novel vaccine for the treatment of ALK-positive lung cancer, increasing response rates and preventing metastasis.
ALK mutations occur in approximately 5-6% of all non-small cell lung cancers and are known as “diamond mutations” due to their favorable response to treatment and longer survival.
However, this doesn’t equate to a complete cure, as most ALK-positive lung cancer patients eventually develop resistance to ALK-TKI treatment.
Despite the relatively good prognosis, the ultimate goal of complete cure remained elusive.
Researchers have developed a vaccine targeting the ALK protein, which helps the immune system more effectively recognize ALK and control tumors. This vaccine can be combined with other drugs to achieve better treatment outcomes.
Since ALK is expressed mainly in tumor cells and not in normal cells, immune therapy targeting ALK is relatively safe.
The study also found that the combination treatment of the ALK vaccine with ALK-TKI and immune checkpoint inhibitors achieved a cure rate of up to 70% and seemed to prevent tumor metastasis.
Brain metastasis is a common issue for ALK mutation patients, severely impacting their treatment outcomes.
However, the ALK vaccine in combination with ALK-TKI and immune checkpoint inhibitors can completely block tumor cell brain metastasis in mice.
Although the ALK vaccine currently has some challenges, such as weak immune responses, the need for further safety confirmation, and tumor immune escape, it offers a new treatment approach.
Future research should focus on developing vaccines that elicit strong ALK-specific T cell responses, confirming their safety in patients, and exploring their combination with other treatment options to enhance efficacy.
We eagerly anticipate not only the successful development of the ALK vaccine but also the emergence of lung cancer vaccines targeting other mutation types, offering the possibility of better prognosis or even a cure for cancer patients.
In Conclusion
In today’s rapidly evolving landscape of cancer treatments, the battle against cancer is no longer a short-term skirmish but a long-term commitment.
In the fight against cancer, patients and experts working together effectively utilize the “weapons” of clinical treatment, which are crucial to achieving victory.
References:
[1] The Eighth Edition Lung Cancer Stage Classification. Detterbeck et al. CHEST (2017); 151(1): 193-203.
[2] J. Van Der Veen, S. Peeters, D. De Ruysscher, et al. Treatment of early-stage non-small cell lung cancer with stereotactic ablative radiotherapy. 2015.
Breakthrough in Lung Cancer Vaccine: 100% Prevention of Brain Metastasis and Increased Cure Rate
(source:internet, reference only)
Disclaimer of medicaltrend.org
